TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26486517
Drug: Tariquidar in
Normalized name: Tariquidar
DrugBank: Tariquidar (DB06240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tariquidar in combination with vinorelbine
Study: 27581680
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg/day) for 180 days
Study: 26488691
Drug: Total knee
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total knee replacement followed by 12 weeks of nonsurgical treatment
Study: 26488691
Drug: Nonsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical treatment alone
Study: 26488758
Drug: Preoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiation therapy (specific dosage not mentioned)
Study: 26490100
Drug: Osmolarity equation:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osmolarity equation: osmolarity=1.86×(Na++K+)+1.15×glucose+urea+14 (all measured in mmol/L)
Study: 26490103
Drug: Agalsidase-beta (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agalsidase-beta (1 mg/kg/2 weeks) with antiproteinuric therapy (ACE inhibitors or ARBs)
Study: 26490491
Drug: Hunger ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hunger ratings recorded twice daily (both P = 0.02)
Study: 26490491
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma concentrations of insulin increased by 120% ± 15% (P = 0.02)
Study: 26490645
Drug: Orbital Atherectomy
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orbital Atherectomy System (OAS) followed by adjunctive balloon angioplasty (BA)
Study: 26491799
Drug: Erythropoietin administration
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin administration and transfusion threshold
Study: 26492842
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of phonation and reflux events
Study: 26492847
Drug: Lactulose challenge
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lactulose challenge test (25 g lactulose in a liquid breakfast of 400 mL Nutridrink)
Study: 26492921
Drug: Modified sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified sham feeding (MSF) with atropine (1 mg bolus 45 min before MSF + 80 ng·kg(-1)·min(-1) for 2 h)
Study: 26496767
Drug: Pegvisomant (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegvisomant (single dose)
Study: 26497198
Drug: Decitabine 5
Normalized name: decitabine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine 5 mg/m(2)/day for 5 consecutive days with 4-week intervals, individualized doses for Cycles 2 to 4 based on pharmacokinetic-pharmacodynamic modeling.
Study: 26497198
Drug: Decitabine (individualized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decitabine (individualized doses for Cycles 2 to 4)
Study: 26497198
Drug: Initial doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial doses for cohorts 2 to 5 were 4, 5, 5.5, and 5 mg/m(2)/day, respectively; median maintenance dose was 7 mg/m(2)/day.
Study: 26499927
Drug: Plasma levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma levels of galectin-9 above 690 pg/mL
Study: 26499927
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of galectin-9 level and Model For End-Stage Liver Disease score
Study: 26500339
Drug: Sequential scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scheme (9 cycles of VMP followed by 9 cycles of Rd; n = 118)
Study: 26500339
Drug: Sequential scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scheme
Study: 26503201
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) doses of greater than 80.5 Gy (median, 58.05 Gy)
Study: 26503201
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) doses of lower than 80.5 Gy
Study: 26503201
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) doses of greater than 80.5 Gy
Study: 26503811
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (r-hGH)
Study: 26504182
Drug: Sirolimus as
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus as monotherapy
Study: 26506438
Drug: 13-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13-valent pneumococcal conjugate vaccine (PCV-13)
Study: 26507836
Drug: KHK2866 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK2866 (0.3, 1, and 3 mg/kg) intravenously once weekly
Study: 26507836
Drug: KHK2866 (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK2866 (0.1 mg/kg)
Study: 26507836
Drug: KHK2866 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK2866 (all doses)
Study: 26508138
Drug: Tramadol (200-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (200-mg extended-release tablets)
Study: 26508901
Drug: Chemotherapy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy without ifosfamide/etoposide
Study: 26508901
Drug: Age, treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age, treatment, tumor location, and tumor size
Study: 26509071
Drug: Corticosteroids >5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids >5 mg/day
Study: 26509071
Drug: Corticosteroids ≤5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids ≤5 mg/day
Study: 26509071
Drug: Continued corticosteroid
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued corticosteroid treatment
Study: 26510696
Drug: Warfarin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin treatment (mean duration 1 year, mean INR 1.9 for IPAH, 2.0 for SSc-PAH)
Study: 26510696
Drug: Warfarin-naïve patients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin-naïve patients (matched control group)
Study: 26511221
Drug: Novel oral
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel oral anticoagulants (NOACs) administered intermittently based on ICM guidance
Study: 26511221
Drug: Intermittent NOAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent NOAC administration
Study: 26511652
Drug: Fluorinated (19F)
Normalized name: fluorine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorinated (19F) agent CS-1000 labeled SVF cells
Study: 26511835
Drug: Wood smoke
Normalized name: Wood creosote
DrugBank: Wood creosote (DB13271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wood smoke exposure (PM1 concentration at 314 μg/m(3) for 3 hours)
Study: 26512876
Drug: Continuous afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous afatinib 30 mg plus nintedanib 150 mg
Study: 26512876
Drug: Intermittent afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intermittent afatinib 40 mg plus nintedanib 150 mg
Study: 26514315
Drug: Fostamatinib 100
Normalized name: fostamatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fostamatinib 100 mg BID co-administered with digoxin 0.25 mg once daily on days 9 to 15
Study: 26514315
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg BID on day 1 and 0.25 mg once daily on days 2 to 8
Study: 26514334
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (splenectomy and SAE)
Study: 26514420
Drug: Vaccine alone
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine alone (10 μg dLPS)
Study: 26514420
Drug: Vaccine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine plus CPG 7909 (250 or 500 μg)
Study: 26514928
Drug: Behavioral support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral support techniques (preparation, distraction, coaching, reinforcement) during in-office tympanostomy tube placement
Study: 26515198
Drug: Recombinant tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant tissue-type plasminogen activator (r-tPA) treatment
Study: 26515457
Drug: Once-daily Basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Basal Insulin (BI) therapy in the morning
Study: 26515457
Drug: Once-daily Basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily Basal Insulin (BI) therapy
Study: 26518132
Drug: 14-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment (T14) with chloroquine (CQ) for 3 days (10, 10, and 5 mg/kg) and primaquine (PQ) daily for 14 days (0.25 mg/kg)
Study: 26518132
Drug: Intermittent single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent single dose (ISD) regimen with a single dose of CQ (10 mg/kg) and PQ (0.75 mg/kg) on days 0, 30, 60, 180, 210, and 240
Study: 26518132
Drug: 14-day treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-day treatment (T14)
Study: 26518736
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of three neuropsychological tests (five-word, cognitive disorders examination, verbal fluency)
Study: 26518979
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) monotherapy at an initial dose of 0.3 mg/kg/day for 2 weeks, followed by 0.6 mg/kg/day for an additional 2 weeks, then increased by 0.6 mg/kg/day up to a maximum of 10.2 mg/kg/day or 400 mg/day until seizure free confirmed by HV-EEG.
Study: 26518979
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) monotherapy during the 12-week maintenance phase.
Study: 26518979
Drug: Lamotrigine (LTG)
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine (LTG) monotherapy.
Study: 30773100
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA supplementation (4 g of eicosapentaenoic acid and docosahexaenoic acid daily)
Study: 26525052
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) infusion at a dose of 0.2-1.4 μg/kg/h with symptom-triggered benzodiazepine (10 mg diazepam bolus) as needed
Study: 26525052
Drug: Symptom-triggered 10
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptom-triggered 10 mg boluses of diazepam only
Study: 26526721
Drug: CD133+ autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD133+ autologous stem cells administered intramuscularly
Study: 26526971
Drug: Lacosamide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (up to 400 mg)
Study: 26526984
Drug: Galunisertib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib (80 mg, Cohort-1)
Study: 26526984
Drug: Galunisertib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galunisertib (150 mg, Cohort-2)
Study: 26527676
Drug: Change in
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Change in the Functional Assessment of Cancer Therapy-Bone Marrow Transplant score
Study: 26528503
Drug: Standard contrast-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard contrast-assisted cannulation (CC)
Study: 26529118
Drug: Nortriptyline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 100 mg
Study: 26529238
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of AERAS-402 followed by MVA85A
Study: 26529238
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of AERAS-402
Study: 26531748
Drug: Standard primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard primary treatment according to the stage of disease
Study: 26535053
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure for 10 days
Study: 26535134
Drug: Tabalumab 120
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 120 mg every 4 weeks (120/Q4W)
Study: 26535134
Drug: Tabalumab 90
Normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tabalumab 90 mg every 2 weeks (90/Q2W)
Study: 26535135
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg plus Methotrexate (MTX) for 52 weeks
Study: 26535146
Drug: Delayed-release (DR)
Normalized name: Delayed Release Oral Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed-release (DR) prednisone 5 mg once daily for 12 weeks
Study: 26536893
Drug: Triheptanoin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triheptanoin treatment
Study: 26537529
Drug: Bosutinib 500
Normalized name: bosutinib 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosutinib 500 mg/day
Study: 26537623
Drug: Romiplostim (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (starting dose of 1 μg/kg)
Study: 26537623
Drug: Romiplostim (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (after discontinuation)
Study: 26537623
Drug: Romiplostim (during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romiplostim (during treatment)
Study: 26537851
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow derived MSCs, 1.5 × 10(6) per kg body weight, administered intravenously at 25 and 26 weeks after transplantation.
Study: 26539981
Drug: Rituximab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (1 g at D0, D15, and M6)
Study: 26541511
Drug: Ipilimumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (3 mg/kg, up to four cycles, administered in 3 week intervals)
Study: 26542378
Drug: ONO/GS-4059 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO/GS-4059 (20 mg to 600 mg once daily, with twice-daily regimens of 240 mg and 300 mg)
Study: 26543510
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg daily oral pioglitazone for 28 days
Study: 26543765
Drug: Schedule A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: 3-weekly epirubicin (90 mg/m2) and docetaxel (75 mg/m2) chemotherapy
Study: 26543765
Drug: Schedule B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule B: 2-weekly epirubicin (60 mg/m2) and docetaxel (60 mg/m2) chemotherapy
Study: 26545441
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion post-haemodialysis
Study: 26545441
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 600 mg 1-h i.v. infusion in healthy volunteers
Study: 26545441
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion pre-haemodialysis
Study: 26545441
Drug: Ceftaroline fosamil
Normalized name: Ceftaroline fosamil
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftaroline fosamil 200 mg 1-h i.v. infusion (pre- and post-haemodialysis)
Study: 26545911
Drug: Thrombophilic SNPs
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombophilic SNPs (factor V Leiden, H1299R, prothrombin G20210A, factor XIII V34L, β-fibrinogen -455G → A, plasminogen activator inhibitor-1 4G/5G, human platelet antigen-1 a/b9L33P, methylenetetrahydrofolate reductase C677T and A1298C)
Study: 26547188
Drug: Helical IMRT
Normalized name: Ep-100 (conjugate of luteinizing hormone-releasing hormone with a cationic .alpha.-helical peptide for therapy of lhrh-expressing tumors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helical IMRT of the pelvic lymph nodes (51.0 Gy) with a simultaneous integrated boost to the prostate (76.5 Gy) in 34 fractions, following at least two months of antihormonal treatment before radiotherapy continuing for at least 2 years.
Study: 26547914
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB) patches (5-20 μg/h and 35-70 μg/h)
Study: 26552042
Drug: WEB treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: WEB treatment with antiplatelet agents
Study: 26554651
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate and gemcitabine (1.0 mg/m² eribulin and 1000 mg/m² gemcitabine on days 1 and 8 of a 28-day cycle)
Study: 26556899
Drug: Blood urea
Normalized name: BLOOD UREA NITROGEN TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood urea nitrogen level >8.2 mmol/L
Study: 26556899
Drug: Hemoglobin level
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin level <75 g/L
Study: 26556899
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of all 3 risk factors (blood urea nitrogen >8.2 mmol/L, hemoglobin <75 g/L, muscle strength ≤3)
Study: 26557215
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen of cleanser (7.8% 1-lactic acid, 2% salicylic acid) and anti-aging serum (0.1% alpha hydroxy acids-retinoids, 6.5% 1-lactic acid) with concurrent use of sun protection factor 50+ sunscreen as needed
Study: 26557787
Drug: Stimulus control
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulus control therapy
Study: 26557787
Drug: Random assignment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random assignment to treatments
Study: 26557787
Drug: Preference allocation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preference allocation to chosen treatment
Study: 26559139
Drug: Interferon β-1a
Normalized name: Interferon beta 1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon β-1a 44 μg subcutaneously three times a week (SC tiw)
Study: 26559790
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with escitalopram (mean daily dose 18.62 mg, SD 5.15) and memantine (mean daily dose 13.62 mg, SD 6.67)
Study: 26559790
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with escitalopram and memantine
Study: 26559790
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with escitalopram and memantine in the amnestic mild cognitive impairment subsample (n = 22)
Study: 26560486
Drug: Nintedanib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib plus pemetrexed (500 mg/m2 iv on Day 1, nintedanib 100 mg bid escalating to 200 mg bid on days 2-21)
Study: 26561629
Drug: ¹³C-lycopene (10.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ¹³C-lycopene (10.2 mg)
Study: 26561916
Drug: Bovine activated
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as initial hemostasis in group A (5 mL)
Study: 26561916
Drug: Bovine activated
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bovine activated factors IIa/VIIa/IXa/Xa (SeraSeal) applied topically via catheters as rescue therapy in group B (5 mL)
Study: 26562532
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics (vancomycin 500 mg, gentamycin 40 mg, meropenem 500 mg once-daily for 4 days)
Study: 26562532
Drug: Broad-spectrum antibiotics
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broad-spectrum antibiotics (vancomycin, gentamycin, meropenem)
Study: 26562836
Drug: Synthetic ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synthetic ACTH (intramuscular injections, max 1 mg twice a week for 9 months)
Study: 26562836
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and steroids (historical control)
Study: 26563229
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for generalized anxiety disorder, panic disorder, social anxiety disorder (SAD), or post-traumatic stress disorder
Study: 26563229
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for social anxiety disorder (SAD)
Study: 26563323
Drug: Latanoprostene bunod
Normalized name: Latanoprostene bunod
DrugBank: Latanoprostene bunod (DB11660)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Latanoprostene bunod 0.024% instilled once daily (QD) for 14 days
Study: 26565008
Drug: RBX2660 (microbiota
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBX2660 (microbiota suspension) administered via enema